• About
• Links
• Contact
• Sitemap

Sitemap > News > Infectious Diseases

• Cervarix, the GSK cervical cancer candidate vaccine, provides sustained immune response in 100 per cent of women up to 55 years of age
• Human Genome Sciences Announces Positive Final Results of Phase 2b Trial of Albuferon
• XTL PROVIDES UPDATE ON PHASE I CLINICAL TRIAL OF XTL-2125
• KaloBios Initiates a U.S. Phase 1 Study of Its Second Drug Candidate, KB001
• Valopicitabine Combined With Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment In A Phase II Trial
• Vertex Reports 2007 Pipeline Progress
• ViroPharma Announces Completion of Enrollment in 500mg BID Arms of HCV-796 Phase 2 Study
• Boehringer Ingelheim initiates SPRING study of Aptivus (tipranavir) in diverse group of highly treatment-experienced HIV-positive patients
• Boehringer Ingelheim initiates SPRING study of Aptivus (tipranavir) in diverse group of highly treatment-experienced HIV-positive patients
• Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
• Novartis gains European approval for its innovative flu vaccine Optaflu
• US FDA Grants Orphan Drug Status to Immtech
• BIOCRYST PRESENTS PHASE I PERAMIVIR DATA AT THE OPTIONS FOR THE CONTROL OF INFLUENZA CONFERENCE
• Phase I for Influenza vaccine adjuvanted with Intercell’s IC31 started
• Merck Provides Update on Status of Supplemental Biologics License Applications (sBLA) for GARDASIL
• Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
• Immtech Completes Dosing Protocol of Malaria Prevention Trial
• Pfizer Receives Approvable Letter From FDA For Maraviroc
• Theravance Announces Enrollment of Last Patient in Phase 3 Hospital-Acquired Pneumonia Clinical Program with Investigational Antibiotic, Telavancin
• First Ad35-Based HIV-1 Vaccine Enters Phase I Clinical Trial at NIH
• Arpida receives approval from US FDA to initiate a Phase II trial with iclaprim in hospital-acquired, ventilator- and healthcare-associated pneumonia
• PEGINTRON(TM) and REBETOL(R) Combination Therapy Approved in European Union for Treating Hepatitis C in Patients Coinfected With HIV
• Second Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
• Alnylam Initiates Phase II Clinical Trial to Evaluate Safety and Anti-viral Efficacy of ALN-RSV01 in the Treatment of Respiratory Syncytial Virus (RSV) Infection
• Hemispherx Biopharma Initiates Phase IIb Trial in Australia for Ampligen as Vaccine Adjuvant for Seasonal Influenza
• Advancis Pharmaceutical Reports on Meeting with FDA Reviewing Keflex PULSYS Phase III Trial Design
• Dynavax Starts HEPLISAV(TM) Phase 3 in Europe; U.S. Study; and Phase 2 in ESRD in Canada
• Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839
• SciClone Initiates Phase 2 Clinical Trial Using SCV-07 to Treat Hepatitis C Patients
• FDA Priority Review Granted for ISENTRESS™ (raltegravir), Merck's Investigational Integrase Inhibitor for HIV
• Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
• Ceragenix(TM) Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
• MEDIVIR ANNOUNCES BRISTOL-MYERS SQUIBB HAS TERMINATED THEIR AGREEMENT FOR THE DEVELOPMENT OF MEDIVIR'S PRECLINICAL POLYMERASE INHIBITOR, MIV-170
• ViroPharma Initiates Phase 3 Study of CAMVIA(TM) (maribavir) in Liver Transplant Patients
• Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
• NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
• Theravance Announces Positive Results from Phase 2 Clinical Study with Investigational Antibiotic in Patients with Complicated Skin and Skin Structure Infections
• DEPOMED ANNOUNCES RESULTS OF PHASE 3 CLINICAL TRIAL FOR GABAPENTIN GR(TM) IN POSTHERPETIC NEURALGIA
• Peregrine Pharmaceuticals Initiates Bavituximab Clinical Trial in HCV Patients Co-Infected With HIV
• Vical Reaches Initial Enrollment Milestone in Phase 2 Trial of DNA Vaccine Against CMV
• Pharmasset and Roche Initiate Studies to Advance R7128 for HCV
• Abbott Announces Approval of First Fully-Automated Blood Screening Test for Hepatitis C Antibodies
• Valopicitabine Development Program Placed on Clinical Hold in the United States
• First child vaccinated with Intercell JE Vaccine in India - Pediatric Phase II trial started
• Acambis' universal influenza vaccine enters Phase 1 trial
• ARPIDA REPORTS POSITIVE RESULTS OF SECOND PIVOTAL PHASE III TRIAL WITH INTRAVENOUS ICLAPRIM IN CSSSI
• Neurochem receives approvable letter for eprodisate (KIACTA) for treatment of AA amyloidosis
• GeoVax Annouces Start of 2 New HIV/AIDS Vaccine Human Trials
• Metabasis Therapeutics Announces CS-917 Phase 2b Clinical Trial Results and Reports on Status of Pradefovir
• Mpex Pharmaceuticals Initiates Multi-dose Clinical Trial in the U.S. with MP-376 in Patients with Cystic Fibrosis
• NUCRYST Pharmaceuticals receives FDA clearance of antimicrobial barrier topical cream
• Pfizer Receives Positive Opinion from CHMP for Celsentri (maraviroc) for Treatment-Experienced Patients Infected with CCR5-Tropic HIV-1
• Smaller size capsules of flu drug Tamiflu receive positive opinion in Europe
• Phase IIa Study Results Demonstrate that Once-Daily 200 mg Dosing of INCB9471 Provided Potent and Prolonged Antiviral Activity in HIV-Infected Patients
• BIOCRYST INITIATES PHASE II CLINICAL TRIAL TO EVALUATE INTRAVENOUS PERAMIVIR IN PATIENTS HOSPITALIZED WITH INFLUENZA
• Vicriviroc Demonstrates Potent Viral Suppression Through 48 Weeks of Therapy in ACTG Phase II Study in Treatment-Experienced HIV Patients
• Maraviroc Reduces HIV Viral Load in Treatment-Naive Patients, 48 Week Data Show
• OctoPlus announces promising results for Locteron Phase IIa clinical study
• Development Discontinued for ANA975, an Early Stage Compound for Treatment of Hepatitis C Virus Infection
• AlphaVax Announces Interim Results from Phase 1 Influenza Vaccine Clinical Trial
• AVANT Commences Phase 2 Clinical Trial of Its Single Dose, Oral Typhoid Fever Vaccine
• Cadence Pharmaceuticals Announces Agreement With FDA On Increased Enrollment In Phase III Clinical Trial Of Omigard.
• Iomai Vaccine Confers Statistically Significant Protection Against Travelers' Diarrhea in Phase 2 Study
• Novavax Begins Human Clinical Testing of Novel Pandemic Flu Vaccine
• Pharmasset Completes Enrollment of Phase 1 Study of R7128 for HCV
• Lux Granted Fast Track Designation by FDA for LX211 for The Treatment of Uveitis
• Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers' Diarrhea Patch Vaccine
• TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
• Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
• Spectrum Pharmaceuticals Investigational New Drug Application for SPI-1620 Cleared by U.S. Food & Drug Administration
• BIT225 Phase I Clinical Trial Successfully Completed
• Romark Initiates Clinical Trial of Alinia® for Chronic Hepatitis C in the United States
• Inovio Biomedical Partner Tripep Receives Approval to Initiate Phase I/II Study of Novel Vaccine for Hepatitis C Virus
• Intercell's therapeutic Hepatitis C vaccine meets primary endpoints in Phase II interim analysis
• Targeted Genetics Reports Interim Phase II Data From HIV/AIDS Vaccine Clinical Trial
• Artisan Pharma, Inc. Launches Phase 2b Trial of ART-123 for Treatment of DIC in Sepsis
• Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results
• MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
• DRUG IN NEW HEPATITIS C CLINICAL TRIAL
• Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon® Trial Ahead of Schedule
• Meridian Bioscience, Inc. Announces the Commencement of Phase I/II Clinical Trials of Parvovirus B19 Vaccine
• Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
• Astellas Announces the Extension of US Regulatory Review for the sNDA of MYCAMINE
• InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
• Theratechnologies completes patient recruitment for tesamorelin in confirmatory Phase 3 trial
• Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
• FDA Advisory Committee Unanimously Recommends Accelerated Approval of ISENTRESS™ (raltegravir), Merck\'s Investigational Oral Integrase Inhibitor, for Treatment of HIV
• Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
• CUBICIN Approved for Additional Indications in the EU
• Data in the SinuNase Phase 3 Clinical Trial Predicts That Virtually 100% of Chronic Sinusitis Cases Are Due to a Fungal-Induced Inflammation
• Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
• R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
• Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
• Phynova announces completion of patient enrollment for Phase I/II clinical trial of PYN17 in chronic hepatitis C
• Lipsovir® - all patients in the phase III program now enrolled
• TARGANTA INITIATES PHASE 2 ORITAVANCIN INFREQUENT DOSING STUDY
• FDA Approves LEVAQUIN® Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
• Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
• Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
• ISENTRESS™ (raltegravir), in Combination with Optimized Background Therapy (OBT), Provided Sustained Viral Suppression in Highly Treatment-Experienced Patients Infected with HIV, through 48 Weeks
• New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Complicated Skin Infections, Including MRSA
• New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
• New Phase 3 Study In Treatment-Naïve Adults With HIV Evaluates Efficacy And Safety Of Once-Daily PREZISTA™/Ritonavir Vs. Kaletra® As Part Of HIV Combination Therapy
• Sanofi pasteur\'s investigational H5N1 influenza vaccine achieves high immune response at low dosage
• US FDA Grants Orphan Drug Status to Immtech\'s Pafuramidine for Treatment of African Sleeping Sickness
• FDA Approves Expanded Label for FluMist® to Include Children Two to Five Years of Age
• Biocryst Reports Preliminary Results from A Phase II Clinical Trial of Peramivir in Subjects with Acute Influenza
• AdvanDx Launches the First LNA-Based In Vitro Diagnostic Test for Detection of Antibiotic Resistant \"Superbugs\"
• Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV
• View Summary Dynavax\'s HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
• Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
• Promising Early Data from Phase I/II Clinical Trial Using GenVec Vaccine Presented at Malaria Conference
• NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
• European Union\'s CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
• Vaccination and Enrollment Are Discontinued in Phase II Trials of Merck\'s Investigational HIV Vaccine Candidate
• VaxInnate Initiates Phase I Clinical Study of M2e Universal Influenza Vaccine
• InterMune Announces Start of Phase 1b Trial of ITMN-191
• CUBICIN Approved for Marketing in Canada
• U.S. Food & Drug Administration approves CSL influenza virus vaccine, for marketing in the U.S.
• Barrier Therapeutics Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Hyphanox(TM) for Onychomycosis
• Chinese SFDA Grants Immtech Fast Track Status
• Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
• TRANSGENE EXTENDS THERAPEUTIC VACCINE CANDIDATE TG4040 DEVELOPMENT PROGRAM AGAINST CHRONIC HEPATITIS C
• Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
• Theratechnologies Reports Positive 52-Week Phase 3 Results For Its Lead Drug Candidate Tesamorelin
• Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
• Crucell presents Phase I results rabies antibody cocktail showing safety and ability to protect
• MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
• Immtech Announces Interim Analysis In Phase III African Sleeping Sickness Trial
• MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
• GSK seeks prequalification for Cervarix™ from the World Health Organization after obtaining marketing approval in Europe
• Interim Results from a New Trial of CANCIDAS® (caspofungin acetate) in Pediatric Patients with Documented Fungal Infections
• New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections
• Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
• Achillion Reports Safety and Potent Antiviral Activity in Topline Results From Elvucitabine Phase 2 Study in HIV-Infected Patients
• Health Canada Approves ATRIPLA® (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
• Interim Safety Data Favorable for Vical\'s Phase 2 Trial of DNA Vaccine Against CMV
• Omiganan Phase II Rosacea Study Demonstrates Promising Results, Partner Plans to Advance to Phase III
• OctoPlus announces positive Phase IIa efficacy and tolerability results for Locteron in hepatitis C
• FDA Approves DORIBAX for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
• FDA Clears bioMérieux’s VIDAS® B·R·A·H·M·S PCT® Assay A First Indication for Sepsis Risk Assessment in the ICU
• Interim Safety Data Favorable for Vical\'s Phase 2 Trial of DNA Vaccine Against CMV
• Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
• FDA Expands Age Range for Use of Bacterial Meningitis Vaccine
• Barrier Therapeutics Announces Promising Results From On-Going Phase 2a Study of Pramiconazole in Onychomycosis
• Theravance Receives FDA Approvable Letter for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
• CF102 Drug is Effective in Promoting Liver Tissue Regeneration; Clinical Trials with CF102 in the Treatment of Liver Cancer are Due to Commence in Early 2008
• Inhibitex Initiates Phase I Trial of FV-100 for the Treatment of Shingles
• R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
• Flamel Technologies Announces Positive Top Line Results of a Clinical Trial of IFN-alpha-XL versus PegIntron™ in Patients with Chronic Hepatitis C Virus Infection
• Gilead Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients
• Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
• Inovio Biomedical\'s DNA Vaccine Delivery Technology Moves Ahead in Clinical Trial for Hepatitis C
• AlphaVax Announces Results from Phase 1 Influenza Vaccine Clinical Trial
• GlaxoSmithKline initiates trials of Promacta®/Revolade™ (eltrombopag) to investigate the potential to aid hepatitis C patients in achieving sustained virological response
• Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance
• Excellent Results Received from GeoVax’s Full-Dose HIV/AIDS Vaccine Trial
• Gilead Announces 48-Week Data from Two Pivotal Phase III Studies Evaluating Viread(R) For the Treatment of Chronic Hepatitis B
• Gilead Announces Phase I Data for GS 9190, An Investigational Compound for the Treatment of Chronic Hepatitis C
• Human Genome Sciences Announces Full Presentation of Quality-of-Life Results from Phase 2b Trial of Albuferon® for Hepatitis C
• Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon® in Chronic Hepatitis C Patients who Failed to Respond to Previous Therapy
• Immtech Completes Malaria Prevention Trial
• Interim Results from a New Trial of CANCIDAS® (caspofungin acetate) in Pediatric Patients with Documented Fungal Infections
• New Data Presented on GARDASIL®, Merck\'s Cervical Cancer Vaccine, in Women Through Age 45
• Ninety-one Percent of BARACLUDE® (entecavir) Treated Patients in a Four-Year Cohort Demonstrated Virologic Suppression to Undetectable Levels
• Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
• Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C
• Treatment with Pegasys provides hepatitis C patients a second chance to achieve a cure after not responding to Peg-Intron
• Positive Results From Peregrine Pharmaceuticals\' Bavituximab Phase l HCV Trial Presented at AASLD Meeting
• Sanofi Pasteur presents positive results of tetravalent dengue candidate vaccine
• OneWorld Health Launches Phase 4 Program of Paromomycin IM Injection in India
• MacroChem Announces Positive Interim Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis
• GlobeImmune Announces Presentation of Results from a Randomized Phase 1b Study of the GI-5005 Tarmogen in Patients with Chronic Hepatitis C Infection
• GlaxoSmithKline initiates trials of Promacta®/Revolade™ (eltrombopag) to investigate the potential to aid hepatitis C patients in achieving sustained virological response
• Sanofi Pasteur initiates phase II trial of cell culture-based seasonal influenza vaccine
• Invitrogen and Biosynth Partner to Launch Rapid Detection Products for MRSA Contamination in Hospitals
• Data from STEP Study Presented at Open Scientific Session Confirm Merck\'s Investigational HIV Vaccine was not Effective
• FDA Strengthens Boxed Warnings, Approves Other Safety Labeling Changes for Erythropoiesis-Stimulating Agents
• Baxter Receives 510(k) Clearance from FDA for V-Link with VitalShield, New Antimicrobial Intravascular Technology
• ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
• Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra® (lopinavir/ritonavir) Tablet for Pediatric HIV Patients
• Crucell\'s Rabies Antibody Cocktail Granted Fast Track Status
• Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
• BREAKTHROUGH IN HIGH SENSITIVITY TB AND MALARIA DIAGNOSTICS
• Gilead Submits New Drug Application to U.S. FDA for Aztreonam Lysine for Inhalation for Cystic Fibrosis
• BioAlliance Pharma completes patient enrolment ahead of schedule for its pivotal phase III clinical trial of Loramyc® in the USA for the treatment of oropharyngeal candidiasis
• Aradigm Initiates Phase 2 Study of Inhaled Liposomal Ciprofloxacin for Cystic Fibrosis
• Pacgen Initiates a Phase IIB Clinical Trial for PAC-113
• AVANT\'s Oral Combined Enterotoxigenic E. coli-Cholera Vaccine to Enter Phase 1 Safety Study Funded by the NIH
• Initiation of a phase IIa clinical trial with investigational hepatitis C protease inhibitor TMC435350
• Naryx Pharma Announces Completion of Enrollment of a Phase 2b Clinical Trial of Sybryx for Chronic Sinusitis
• NovaBay Announces Positive Phase I Study Results with Its Lead Aganocide Compound
• Inovio Biomedical Partner Tripep Treats First Subject in Phase I/II Study of Novel Hepatitis C DNA Vaccine
• Transport\'s Phase 2 Data Show Single Treatment SoloVir™ ETS Significantly Stops Progression of Cold Sore Episode
• Bavarian Nordic A/S reports positive data from first EUA enabling study with IMVAMUNE® smallpox vaccine
• MIGENIX Reports Preliminary Celgosivir Viral Kinetics Study Four-Week Interim Results
• Merck\'s ROTATEQ® Reduced Hospitalizations and Emergency Department Visits Due to G9P1A[8] Rotavirus by 100 Percent as Shown by Post-hoc Analysis of Data
• Can-Fite: IND submission for Phase I Clinical Trials with its Drug for Liver Diseases CF102. Can-Fite develops CF102 for the treatment of liver cancer, hepatitis virus infections and other liver conditions that represent a current market of about USD 4 billion. Can-Fite estimates that this Phase I study will be initiated in early 2008, subject to FDA approval
• AVANT Immunotherapeutics Achieves Immune Responses Against Cholera, Typhoid and Enterotoxigenic E. coli with a Single-Dose, Oral Combination Vaccine
• Onset Therapeutics Announces FDA Submission for Novel Product for Topical Treatment of Genital Warts
• Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
• RANBAXY RECEIVES APPROVAL TO MANUFACTURE AND MARKET ARV COMBINATION FOR CHILDREN IN INDIA
• Ligand Presents Positive LGD-4665 Phase I Clinical Trial Results at the American Society of Hematology Annual Meeting (ASH)
• HEMISPHERX BIOPHARMA RECEIVES NOTICE OF INCOMPLETE NEW DRUG APPLICATION (NDA)
• Nuvelo Phase 3 SONOMA-2 Trial Shows Alfimeprase has the Potential to Restore Catheter Function
• ZymoGenetics Presents PEG-Interferon Lambda Phase 1a Data
• XTL BIOPHARMACEUTICALS PRESENTS DATA REGARDING ITS HEPATITIS C VIRUS SMALL MOLECULE PROGRAM AT HEP DART 2007 - AN INTERNATIONAL SCIENTIFIC CONFERENCE ON VIRAL HEPATITIS
• First patients enrolled in phase II trial with intravenous iclaprim in HAP/VAP/HCAP
• Alnylam Reports Continued Progress in Clinical Development of ALN-RSV01 for the Treatment of Respiratory Syncytial Virus (RSV) Infection
• Inhibitex Reports Favorable Results from First Clinical Trial of FV-100
• Chimerix Initiates a Multi-dose Clinical Trial of the Company’s Lead Compound, CMX001, for the Treatment for Smallpox Infection
• European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
• Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx® GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
• Valeant Pharmaceuticals Sells HEP-C Drug INFERGEN® to Three Rivers Pharmaceuticals, LLC for $91 Million
• Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
• GlobeImmune Announces Initiation of Phase 2 Clinical Trial of GI-5005 in Patients with Chronic Hepatitis C
• Novavax Announces Favorable Interim Results From Human Clinical Trial For Its Pandemic Influenza Vaccine Program
• Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
• Luminex Receives U.S. Food and Drug Administration Clearance for xTAG Respiratory Viral Panel
• First Molecular Test to Simultaneously Identify Staphylococcus aureus and Methicillin-Resistant Staphylococcus aureus from Positive Blood Cultures
• Theravance Receives Notice of Possible Telavancin Review by FDA Advisory Committee
• Pfizer Receives Approvable Letter from FDA for Dalbavancin
• Immtech Announces Pafuramidine (DB289) Program on Clinical Hold
• Ardea Biosciences\' Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial
• Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
• Acambis reports positive data from trials of universal influenza A vaccine
• Antigenics Reports Positive Data on QS-21 Stimulon® Adjuvant in Acambis’ Influenza A Vaccine
• Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
• Vertex Pharmaceuticals Reports Progress in Development of Investigational HCV Drug Telaprevir and Provides Business Update
• Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
• InterMune Announces Continuing Progress on ITMN-191 (R7227)
• Tacere Therapeutics Enters Collaboration and License Agreement with Pfizer to Develop and Commercialize RNAi Hepatitis C Drug
• Safety Monitoring Committee Recommends That Emergent BioSolutions Continue Its Hepatitis B Immunotherapy Phase II Trial
• BioAlliance Pharma receives market approval for Loramyc® in the United Kingdom and Denmark
• Nucleonics Initiates Hepatitis B Clinical Trial with Expressed Interfering RNA Therapeutic
• Schering-Plough Reports Top-Line Results of the IDEAL Study
• Arpida receives green light from US FDA for Phase II efficacy trial with oral iclaprim
• Roche Responds to Announcement of “IDEAL” Hepatitis C Trial Results
• Progenics Initiates Phase 2 Clinical Trials for PRO 140, a Novel HIV Antibody Therapy
• Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
• FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
• Start of CytoFab Phase 2 Programme in Severe Sepsis
• Arpida reports progress in pivotal phase III trial with TLT treatment in onychomycosis
• Vertex Pharmaceuticals to Begin Phase 3 Development of Telaprevir, Investigational Hepatitis C Protease Inhibitor
• NovaBay Pharmaceutical’s Investigational New Drug Application (IND) for the Prevention of Catheter Associated Urinary Tract Infections Cleared by FDA
• FDA APPROVES ADDITIONAL INDICATION FOR ASTELLAS´ MYCAMINE
• Alnylam Reports Positive Phase II Data for ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection
• New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets
• ImmunoVaccine Technologies Discusses Phase I Clinical Trial Application
• Human Genome Sciences Modifies Dosing in ACHIEVE Trials of Albuferon
• BIOCRYST UPDATES PERAMIVIR CLINICAL DEVELOPMENT PLAN
• FDA Approves MiddleBrook\'s Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
• Abbott\'s Kaletra® and Aluvia® (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
• MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
• MedImmune Submits Biologics License Application to FDA for Motavizumab
• Theratechnologies presents additional results from its tesamorelin 52-week Phase 3 study at the Conference on Retroviruses and Opportunistic Infections
• Pfizer Presents New Data from HIV/AIDS Portfolio at Conference on Retroviruses and Opportunistic Infections
• OctoPlus commences United States Phase IIa study with Locteron for the treatment of hepatitis C
• Merck\'s ISENTRESS® (raltegravir) Tablets in Combination with other Anti-HIV Medicines Maintained Reductions in HIV-1 Viral Load and Increased CD4 Cell Counts Through 48 Weeks of Therapy in Treatment-Experienced Adults
• Inhibitex HIV Integrase Inhibitor Data Presented at 15th Annual Conference on Retroviruses and Opportunistic Infections
• IDX899 Demonstrates Rapid and Profound Inhibition of HIV Replication in a Phase I/II Clinical Trial in Treatment-Naive HIV-Infected Patients
• Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
• Intercell’s therapeutic Hepatitis C vaccine meets primary endpoints in Phase II
• Targanta Submits Oritavancin New Drug Application
• SciClone and Sigma-Tau Report Promising Interim Results From Phase 3 Hepatitis C Trial
• Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx® GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
• ActivBiotics Outlines a Clinical Path Forward to Examine if Rifalazil Is Superior to Azithromycin in the Treatment of Chlamydia STD
• Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
• Avexa Initiates first Phase III Sites
• GSK receives favourable recommendation by FDA advisory committee for Rotarix [rotavirus, live, oral]
• GSK\'s candidate adjuvanted pre-pandemic H5N1 vaccine reaches important EU regulatory milestone
• Arpida provides update on progress of New Drug Application for intravenous iclaprim
• Oculus Innovative Sciences Announces Positive Top-Line Phase II Data with Microcyn® Technology in Mildly Infected Diabetic Foot Ulcers
• Intercell completes Phase I clinical trial for improved seasonal Flu vaccine formulated with IC31
• NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
• Alnylam Achieves First Human Proof of Concept for an RNAi Therapeutic with GEMINI Study
• Theravance Receives Additional Information Regarding FDA Cancellation of Advisory Committee Meeting
• Panacos Announces Discovery of Bevirimat Patient Response Predictors
• Reports of increased survival in bird flu patients taking Tamiflu
• Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
• NovaBay Pharmaceuticals Commences Phase I Human Clinical Trial for the Prevention of Catheter Associated Urinary Tract Infections
• Optimer Pharmaceuticals Completes Enrollment in Phase 3 Clinical Trial of Prulifloxacin in Patients with Travelers’ Diarrhea
• Third Wave\'s HPV Clinical Trial Achieves Primary Clinical Endpoints
• Mobidiag Releases First Microarray Based Rapid Test for Herpesvirus Identification
• Vertex Pharmaceuticals and Tibotec Announce Start of Phase 3 \'ADVANCE\' Study with Telaprevir in Treatment-Naive, Genotype 1 HCV Patients
• Avexa reports superior results in ATC Phase 11b Clinical Trial
• Oculus Innovative Sciences Announces Additional Phase II Data for Microcyn Technology in Mildly Infected Diabetic Foot Ulcers
• Dynavax and Merck & Co., Inc. Report Clinical Hold of Investigational Vaccine HEPLISAV
• Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
• NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
• Hepatitis C Virus DNA Vaccine Shows Safety When Delivered by Inovio Biomedical\'s Electroporation Delivery System in Phase I/II Clinical Study at Karolinska University Hospital
• VALEANT PHARMACEUTICALS REPORTS ENCOURAGING PHASE IIb RESULTS AT TREATMENT WEEK 12 FOR TARIBAVIRIN
• Lipsovir® prevents cold sores. Phase III clinical trial results first to show prevention by early treatment
• Arpida submits New Drug Application for intravenous iclaprim for treatment of skin infections
• FDA issues Approvable Letter for ceftobiprole, a new anti-MRSA broad-spectrum antibiotic
• Supplemental Application for GARDASIL®, Merck\'s Cervical Cancer Vaccine, Designated Priority Review by the U.S. FDA for Use in Women 27 through 45
• SIGA Files Application Supporting Emergency Use Approval for ST-246
• NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
• THALLION PROVIDES UPDATE ON SHIGAMABS PROGRAM
• Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
• KaloBios Initiates Phase 1/2 Trial of Humaneered Monoclonal Antibody KB001 for Treatment of Pseudomonas Infections in Cystic Fibrosis Patients
• InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
• InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
• AVANT\'s Single-Dose Oral Ty800 Vaccine Meets Primary Endpoints in Phase 2 Study
• FDA approves Rotarix [Rotavirus Vaccine, live, oral], the first vaccine licensed to complete the rotavirus immunisation series by four months of age
• Crucell Announces First in Man Study with New Adenovirus Vector
• Thermo Fisher Scientific Receives FDA Clearance for MRSA Test Medium
• TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
• LANI Phase II patient enrolment in second Asian Co
• TARGANTA ANNOUNCES FDA ACCEPTANCE OF ORITAVANCIN NEW DRUG APPLICATION
• B·R·A·H·M·S Receives Final FDA Clearance To Market Procalcitonin (PCT)
• Alnylam Initiates Phase II Trial to Evaluate Safety and Tolerability of ALN-RSV01 in Adult Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus (RSV) Infection
• Aeras, Crucell and SATVI Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
• Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
• Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea
• Arpida provides further comments on the pivotal Phase III trials
• ICLL\'s vaccine against JE: Excellent safety & immunogenicity in pediatric Phase II trials
• Inhibitex Presents Encouraging Phase I Data on FV-100
• Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
• Dynavax and Merck & Co., Inc. Update Status of Clinical Hold of Investigational Vaccine HEPLISAV
• Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx® GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
• Calypte\'s Aware(TM) HIV-1/2 OMT Approved as China\'s Only Rapid Oral HIV Test
• AlphaVax Announces Initial Analysis of Data from CMV Phase 1 Clinical Trial
• ViroPharma Announces Discontinuation of HCV-796 Development
• Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
• BioAlliance Pharma announces preliminary results from the pivotal US phase III trial for Loramyc
• Replidyne Discontinues Phase III Trial
• Gilead Announces 72-Week Data From Two Pivotal Phase III Studies Evaluating Viread(R) for the Treatment of Chronic Hepatitis B
• Telaprevir-Based PROVE Studies Show Significantly Higher SVR Rates in Treatment-Naive Genotype 1 Hepatitis C Patients in Half the Time of Current Treatments
• Vertex Announces Positive Interim Results with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients who Failed to Achieve SVR with Previous Pegylated Interferon & Ribavirin Treatment
• Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compound MitoQ
• BIOLEX THERAPEUTICS RESEARCHERS PRESENT LOCTERON PHASE 2a HEPATITIS C TRIAL RESULTS AT EASL CONFERENCE
• View Summary Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
• First data on TMC435350 in patients with hepatitis C who have failed previous treatment shows antiviral activity
• Third Wave Completes FDA Submissions for Its Two HPV Products
• Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
• Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
• Roche’s Investigational Hepatitis C Polymerase Inhibitor, R1626, Demonstrated Significant End-of-Treatment Response in Phase IIa Study
• Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
• Flamel Technologies Presents Results of Two Week Study of Interferon Alpha XL at the European Association for the Study of the Liver
• European Commission Approves Viread(R) for Chronic Hepatitis B
• Clinical Update – Debio 025 in Hepatitis C - Presentation of Phase IIa Efficacy Results
• VALEANT PHARMACEUTICALS HIGHLIGHTS TARIBAVIRIN PHASE IIb DATA PRESENTATION AT EUROPEAN ASSOCIATION FOR THE STUDY OF LIVER (EASL) ANNUAL MEETING
• Mirabilis Completes First Human Trial
• Inhibitex Initiates Phase I Trial of FV-100 for the Treatment of Shingles
• SinuNase(TM) Fast-Tracked Pivotal Phase 3 Study in Chronic Sinusitis Shows Statistically Significant Objective Evidence of Superiority of SinuNase Over Control Lavage in Severe Cases
• Beckman Coulter Acquires Rights to Hepatitis C Virus
• Protez Initiates Phase II Study for Its Lead Product PZ-601 in Infectious Diseases
• Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients with
• Can-Fite Successfully Completed Phase I Clinical Trial with its 2nd Drug CF102. Prepares for next phase of clinical trials in liver diseases.
• Novartis Menveo® vaccine shows superior immune response against four types of meningitis disease in pivotal phase III trial
• Regulatory Filing for FACTIVE Tablets Submitted in Europe
• PolyMedix Receives Regulatory Clearance to Initiate Phase I Clinical Study of Novel Systemic Antibiotic Compound
• Virostatics Doses First Patient in Phase IIa Trial of VS411 for the Treatment of HIV Infection
• Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
• PHASE II CLINICAL TRIAL OF SINOBIOMED’S MALARIA CANDIDATE VACCINE TO START IN Q3
• MEDIVIR AB BROADENS ITS HEPATITIS C COLLABORATION WITH TIBOTEC, ENTERING A PARTNERSHIP IN THE FIELD OF HCV POLYMERASE
• CDC Recommends ZOSTAVAX®, Merck\'s Shingles Vaccine, for All Appropriate Adults Aged 60 and Older
• Arpida announces FDA acceptance of the iclaprim New Drug Application